top of page

Recent Posts

Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse

Nov 4, 2022

1 min read

Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination.

Read more: https://www.roswellpark.org/newsroom/202211-pediatric-multicenter-study-shows-targeted-therapy-high-risk-hodgkin-lymphoma

Comments

Unexpected discovery points to a possible route for childhood brain tumor treatments

Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

Removing immune 'brake' improves CAR T-cell therapy for pediatric bone cancer

Cardiometabolic Risk in Childhood Cancer Survivors Treated With Anthracyclines

Hodgkin Lymphoma Survivors Face Higher Long-Term Mortality

Emotional health supports physical health in survivors of childhood cancer

Hidden aggressive cells reveal why some lower-risk childhood cancers turn deadly

Personalized T-cell therapy eliminates detectable metastatic kidney tumor in adolescent after multiple relapses

Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends

MBNL1 was identified as a potential cancer drug target for a type of childhood leukemia

Archive

Search By Tags

bottom of page